ERBB2 and urinary bladder carcinoma: It was found that HER2 was weakly expressed in bladder cancer from the collected cases of bladder cancer, so the quality of immunohistochemical staining determined the regimen of neoadjuvant chemotherapy or targeted therapy for patients.